Pain Therapeutics Revamps Oxytrex Program, Changes Phase III Protocol For Pain
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pain Therapeutics' new trial design for Oxytrex features ultra-low doses and a four-times-a-day dosing regimen, CEO Remi Barbier said May 4